Hughes Thomas, Zhang David, Nair Priya, Buscher Hergen
Department of Intensive Care Medicine, St Vincent's Hospital, Sydney 2010, Australia.
Faculty of Medicine, University of New South Wales, Sydney 2052, Australia.
Membranes (Basel). 2021 Mar 30;11(4):251. doi: 10.3390/membranes11040251.
Blood product administration plays a major role in the management of patients treated with extracorporeal membrane oxygenation (ECMO) and may be a contributor to morbidity and mortality.
We performed a systematic review of the published literature to determine the current usage of packed red cell transfusions. Predefined search criteria were used to identify journal articles reporting transfusion practice in ECMO by interrogating EMBASE and Medline databases and following the PRISMA statement.
Out of 1579 abstracts screened, articles reporting ECMO usage in a minimum of 10 adult patients were included. Full texts of 331 articles were obtained, and 54 were included in the final analysis. All studies were observational (2 were designed prospectively, and two were multicentre). A total of 3808 patients were reported (range 10-517). Mean exposure to ECMO was 8.2 days (95% confidence interval (CI) 7.0-9.4). A median of 5.6% was not transfused (interquartile range (IQR) 0-11.3%, 19 studies). The mean red cell transfusion per ECMO run was 17.7 units (CI 14.2-21.2, from 52 studies) or 2.60 units per day (CI 1.93-3.27, from 49 studies). The median survival to discharge was 50.8% (IQR 40.0-64.9%).
Current evidence on transfusion practice in ECMO is mainly drawn from single-centre observational trials and varies widely. The need for transfusions is highly variable. Confounding factors influencing transfusion practice need to be identified in prospective multicentre studies to mitigate potential harmful effects and generate hypotheses for interventional trials.
血液制品的输注在接受体外膜肺氧合(ECMO)治疗的患者管理中起着重要作用,并且可能是发病和死亡的一个因素。
我们对已发表的文献进行了系统综述,以确定浓缩红细胞输注的当前使用情况。通过检索EMBASE和Medline数据库并遵循PRISMA声明,使用预定义的搜索标准来识别报告ECMO输血实践的期刊文章。
在筛选的1579篇摘要中,纳入了至少报告10例成年患者ECMO使用情况的文章。获得了331篇文章的全文,其中54篇纳入最终分析。所有研究均为观察性研究(2项为前瞻性设计,2项为多中心研究)。共报告了3808例患者(范围为10 - 517例)。ECMO的平均暴露时间为8.2天(95%置信区间(CI)7.0 - 9.4)。未输血的中位数为5.6%(四分位间距(IQR)0 - 11.3%,19项研究)。每次ECMO运行的平均红细胞输注量为17.7单位(CI 14.2 - 21.2,来自52项研究)或每天2.60单位(CI 1.93 - 3.27,来自49项研究)。出院时的中位生存率为50.8%(IQR 40.0 - 64.9%)。
目前关于ECMO输血实践的证据主要来自单中心观察性试验,且差异很大。输血需求高度可变。需要在前瞻性多中心研究中确定影响输血实践的混杂因素,以减轻潜在的有害影响并为干预试验生成假设。